TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Swedish Spinal Stenosis Study. An RCT Comparing Decompression With Fusion to Decompression Only in Lumbar Spinal Stenosis With or Without Degenerative Olisthesis.
Brief Summary: A national randomized multicentre trial (RCT) where decompression is compared with decompression with simultaneous fusion in 245 patients with spinal stenosis on one or two adjacent lumbar levels with or without degenerative olisthesis. The material is stratified for the existence of degenerative olisthesis \>3mm. Monitoring is performed with clinical results from patient surveys after 2 and five years, and with radiological follow-up (MRI, CT and plain X-ray) and an objective function test (6 min walking test) after 2 years. The null hypothesis is that there is no difference in results between the two interventions.


Options:
A: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2
C: Arm Label: Decompression without fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression without fusion | Arm Label: Decompression with fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression with fusion | Intervention Type: PROCEDURE; Name: Decompression without fusion; Assigned to Arm(s): Decompression without fusion | Intervention Type: PROCEDURE; Name: Decompression with fusion; Assigned to Arm(s): Decompression with fusion
D: Arm Label: Posterolateral Fusion w/Pedicle Screws; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompression, Device: Posterolateral Fusion and Implantation of Pedicle Screws | Arm Label: coflex Interlaminar Technolgy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompression, Device: Implantation of coflex Interlaminar Technology | Intervention Type: PROCEDURE; Name: Decompression; Assigned to Arm(s): Posterolateral Fusion w/Pedicle Screws, coflex Interlaminar Technolgy | Intervention Type: DEVICE; Name: Posterolateral Fusion and Implantation of Pedicle Screws; Assigned to Arm(s): Posterolateral Fusion w/Pedicle Screws | Intervention Type: DEVICE; Name: Implantation of coflex Interlaminar Technology; Assigned to Arm(s): coflex Interlaminar Technolgy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.
Brief Summary: The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg \[two 90 mg tablets\] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs acetylsalicylic acid (ASA)-aspirin (300 mg \[three 100 mg tablets\] loading dose on Day 1 followed by 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction \[MI\], and death) in patients with acute ischaemic stroke or transient ischaemic attack (TIA).


Options:
A: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
B: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
C: Arm Label: Early start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Early start of NOAC | Arm Label: Late start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Late start of NOAC | Intervention Type: OTHER; Name: Early start of NOAC; Assigned to Arm(s): Early start of NOAC | Intervention Type: OTHER; Name: Late start of NOAC; Assigned to Arm(s): Late start of NOAC
D: Arm Label: Endovascular thrombolysis; Type: EXPERIMENTAL; Interventions: Drug: Endovascular thrombolysis | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Intervention Type: DRUG; Name: Endovascular thrombolysis; Assigned to Arm(s): Endovascular thrombolysis | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Standard treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.
Brief Summary: The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg \[two 90 mg tablets\] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs acetylsalicylic acid (ASA)-aspirin (300 mg \[three 100 mg tablets\] loading dose on Day 1 followed by 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction \[MI\], and death) in patients with acute ischaemic stroke or transient ischaemic attack (TIA).


Options:
A: Arm Label: TICAGRELOR; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: TICAGRELOR PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): TICAGRELOR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TICAGRELOR PLACEBO
B: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
C: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A
D: Arm Label: Alteplase Placebo + Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase Placebo, Drug: Aspirin | Arm Label: Alteplase + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Alteplase, Drug: Aspirin Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): Alteplase + Aspirin Placebo | Intervention Type: DRUG; Name: Alteplase Placebo; Assigned to Arm(s): Alteplase Placebo + Aspirin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Alteplase Placebo + Aspirin | Intervention Type: DRUG; Name: Aspirin Placebo; Assigned to Arm(s): Alteplase + Aspirin Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.
Brief Summary: The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg \[two 90 mg tablets\] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs acetylsalicylic acid (ASA)-aspirin (300 mg \[three 100 mg tablets\] loading dose on Day 1 followed by 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction \[MI\], and death) in patients with acute ischaemic stroke or transient ischaemic attack (TIA).


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
C: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
D: Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.
Brief Summary: The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg \[two 90 mg tablets\] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs acetylsalicylic acid (ASA)-aspirin (300 mg \[three 100 mg tablets\] loading dose on Day 1 followed by 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction \[MI\], and death) in patients with acute ischaemic stroke or transient ischaemic attack (TIA).


Options:
A: Arm Label: Aspirin + clopidogrel + oral anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Arm Label: Oral anticoagulants + clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Intervention Type: DEVICE; Name: PCI (percutaneous coronary intervention); Assigned to Arm(s): Aspirin + clopidogrel + oral anticoagulation, Oral anticoagulants + clopidogrel
B: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
C: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
D: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)
Brief Summary: This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fx-1006A | Intervention Type: DRUG; Name: Fx-1006A; Assigned to Arm(s): 1
B: Arm Label: Inotersen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inotersen | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Inotersen; Assigned to Arm(s): Inotersen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Tafamidis - 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Tafamidis | Arm Label: Tafamidis - 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Tafamidis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Tafamidis - 20 mg | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Tafamidis - 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: patisiran (ALN-TTR02); Type: ACTIVE_COMPARATOR; Interventions: Drug: patisiran (ALN-TTR02) | Arm Label: Sterile Normal Saline (0.9% NaCl); Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile Normal Saline (0.9% NaCl) | Intervention Type: DRUG; Name: patisiran (ALN-TTR02); Assigned to Arm(s): patisiran (ALN-TTR02) | Intervention Type: DRUG; Name: Sterile Normal Saline (0.9% NaCl); Assigned to Arm(s): Sterile Normal Saline (0.9% NaCl)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomised Study on Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High Flow Nasal Cannula Oxygen.
Brief Summary: Preoxygenation is routinely performed before endotracheal intubation. In the intensive care unit, preoxygenation is often accomplished using a nose-mouth mask. It seems probable that high flow nasal cannula oxygen, which is used in the treatment of patients with hypoxemic respiratory failure, is equally effective in preventing the development of hypoxemia during intubation. In this prospective randomized study preoxygenation using high flow nasal cannula oxygen is compared with preoxygenation via nose-mouth mask in patients with hypoxemic respiratory failure.


Options:
A: Arm Label: Pre-oxygenation with a standard anaesthetic face mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard anaesthetic face mask | Arm Label: Pre-oxygenation using Optiflow and THRIVE technique; Type: EXPERIMENTAL; Interventions: Device: Optiflow and THRIVE technique | Intervention Type: DEVICE; Name: Optiflow and THRIVE technique; Assigned to Arm(s): Pre-oxygenation using Optiflow and THRIVE technique | Intervention Type: DEVICE; Name: Standard anaesthetic face mask; Assigned to Arm(s): Pre-oxygenation with a standard anaesthetic face mask
B: Arm Label: Nose-mouth mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Nose-mouth mask, Procedure: Intubation | Arm Label: High flow nasal cannula oxygen; Type: EXPERIMENTAL; Interventions: Device: High flow nasal cannula oxygen, Procedure: Intubation | Intervention Type: DEVICE; Name: Nose-mouth mask; Assigned to Arm(s): Nose-mouth mask | Intervention Type: DEVICE; Name: High flow nasal cannula oxygen; Assigned to Arm(s): High flow nasal cannula oxygen | Intervention Type: PROCEDURE; Name: Intubation; Assigned to Arm(s): High flow nasal cannula oxygen, Nose-mouth mask
C: Arm Label: High flow oxygen therapy by nasal cannula; Type: EXPERIMENTAL; Interventions: Device: High flow oxygen therapy by nasal cannula. Optiflow® | Arm Label: Facial mask oxygenation in BIPAP ventilation; Type: ACTIVE_COMPARATOR; Interventions: Device: Facial mask oxygenation in BIPAP ventilation | Intervention Type: DEVICE; Name: High flow oxygen therapy by nasal cannula. Optiflow®; Assigned to Arm(s): High flow oxygen therapy by nasal cannula | Intervention Type: DEVICE; Name: Facial mask oxygenation in BIPAP ventilation; Assigned to Arm(s): Facial mask oxygenation in BIPAP ventilation
D: Arm Label: High flow oxygen delivery; Type: EXPERIMENTAL; Interventions: Device: High flow nasal cannula oxygen delivery | Arm Label: Low Flow oxygen delivery; Type: EXPERIMENTAL; Interventions: Device: Low flow nasal cannula oxygen delivery | Arm Label: Standard practice of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: High flow nasal cannula oxygen delivery; Assigned to Arm(s): High flow oxygen delivery | Intervention Type: DEVICE; Name: Low flow nasal cannula oxygen delivery; Assigned to Arm(s): Low Flow oxygen delivery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of a Single Session of Ear Acupuncture in Pain Sensation and Body Balance
Brief Summary: The aim of the present project is to examine the effects of single session of French ear acupuncture on pain sensation and on postural control in individuals with chronic low back pain.

We hypothesize that:

I) The application of French ear acupuncture at specific points to reduce low back pain would decrease pain intensity in patients with chronic low back pain.

II) The pain reduction would be greater for those individuals with low back pain who receive application of French ear acupuncture at specific points to reduce low back pain compared with patients who receive placebo treatment.

III) The application of French ear acupuncture at specific points to reduce back pain will have positive effect on the performance of the postural control system.


Options:
A: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Integrative care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Integrative care | Intervention Type: PROCEDURE; Name: Integrative care; Assigned to Arm(s): Integrative care | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: Acupuncture 1; Type: EXPERIMENTAL; Interventions: Other: Acupuncture 1 | Arm Label: Acupuncture 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Acupuncture 2 | Intervention Type: OTHER; Name: Acupuncture 1; Assigned to Arm(s): Acupuncture 1 | Intervention Type: OTHER; Name: Acupuncture 2; Assigned to Arm(s): Acupuncture 2
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non needle control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Acupuncture - Standardized Points; Type: SHAM_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Accupunture - Experimental Points; Type: EXPERIMENTAL; Interventions: Procedure: Accupuncture | Intervention Type: PROCEDURE; Name: Accupuncture; Assigned to Arm(s): Accupunture - Experimental Points, Acupuncture - Standardized Points, non needle control
D: Arm Label: French ear acupuncture; Type: EXPERIMENTAL; Interventions: Device: French ear acupuncture | Arm Label: Sham Ultrasound; Type: PLACEBO_COMPARATOR; Interventions: Other: Sham Ultrasound | Intervention Type: DEVICE; Name: French ear acupuncture; Assigned to Arm(s): French ear acupuncture | Intervention Type: OTHER; Name: Sham Ultrasound; Assigned to Arm(s): Sham Ultrasound

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cilostazol Stroke Prevention Study for Antiplatelet Combination
Brief Summary: To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol (Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for secondary prevention of ischemic stroke in high-risk patients for stroke


Options:
A: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A
B: Arm Label: Aspirin + clopidogrel + oral anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Arm Label: Oral anticoagulants + clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Intervention Type: DEVICE; Name: PCI (percutaneous coronary intervention); Assigned to Arm(s): Aspirin + clopidogrel + oral anticoagulation, Oral anticoagulants + clopidogrel
C: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel, Drug: Aspirin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel placebo, Drug: Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Monotherapy | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Combination therapy, Monotherapy
D: Arm Label: Monotherapy group; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel | Arm Label: DAPT group; Type: EXPERIMENTAL; Interventions: Drug: aspirin, Drug: clopidogrel, Drug: cilostazol | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): DAPT group, Monotherapy group | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): DAPT group, Monotherapy group | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): DAPT group

Answer: D